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A PHARMACOLOGICAL STRATEGY AGAINAST AFRICAN SLEEPING SICKNESS
Wahaj Zuberi, B.S.
Advisory Professor: Nayun Kim, Ph.D.

Trypanosoma brucei is a parasitic eukaryote and is the causal agent of the
disease known as African sleeping sickness, transmitted via the bite of a tsetse fly. If
left untreated, the parasite ultimately crosses the blood-brain barrier eventually
leading to death. Currently there are five approved drugs used to treat it, each with
toxic side effects and effective at specific disease stages. A more effective and less
toxic drug candidate is highly sought after. The essential enzyme, dUTPase, may be
an excellent drug target in the parasite and can be tested utilizing S. cerevisiae as a
model system.
dUTPase is essential in T. brucei (tbdUTPase), yeast (yDut1), and humans
(hDUT). dUTPase being a dimer in T. brucei, but a trimer in yeast and humans, we
hypothesize there may be a molecule that inhibits the function of tbdUTPase, but not
of yDut1 and hDUT. The endogenous yDut1 was knocked down via auxin inducible
degron system in order to complement its loss by transforming plasmids containing
human and T. brucei dUTPase genes. Induced expression of hDUT and tbdUTPase
did not seem to complement the loss of yDut1. As an alternative strategy, the
dUTPase genes from human and T. brucei were next integrated into the yeast
genome at the inactive HO locus. The results of this experiment were inconclusive
and remain to be further explored.
In order to identify a small molecule ligand of tbdUTPase, a high throughput
virtual drug screen was performed through Schrödinger’s Suite. This led to the
discovery of 13 molecules that bind to tbdUTPase but not to hDUT. Out of the 13,
one molecule showed cytotoxic effects against the parasite but not against yeast.
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To determine if the single molecule found was dUTPase specific, yDut1,
hDUT, and tbdUTPase proteins were purified and their enzymatic activity was
measured in the presence of the single molecule. The results indicated that the
molecule found to have cytotoxic effect against T. brucei cells was not dUTPase
specific. Although the results do not support the initial hypothesis, the dUTPase
pathway, as well as virtual drug screening hold promise and require further research.
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Chapter 1: Introduction
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1.1

African Sleeping Sickness
Human African trypanosomiasis, or African sleeping sickness, is an infectious

disease caused by the parasitic eukaryote Trypanosoma brucei. Transmitted by the
bite of a tsetse fly, this disease is a significant problem and restricted to the subSaharan region of Africa [1]. There are two pathogenic subspecies of T. brucei: 1) T.
b. gambiense is the causal agent of Western African sleeping sickness, responsible
for over 90% of sleeping sickness cases, and causes chronic sleeping sickness; 2)
T. b. rhodesiense is the causal agent of Eastern African sleeping sickness and
causes more acute sleeping sickness [2].
There are two stages to the disease, the first is called the hemo-lymphatic
stage, in which the parasite is present in the bloodstream and lymphatic system, and
the second is called the meningo-encephalitic stage where the parasite has crossed
the blood-brain barrier resulting in neurological damage [1]. Ultimately if left
untreated, patients gradually progress into a coma followed by possible organ failure
and finally death. Rhodesiense sleeping sickness progresses faster with death
resulting within months, whereas death with Gambiense sleeping sickness can take
years [3]. The signs and symptoms of the disease caused by the two subspecies are
overall the same In the first stage of the disease, the leading and most common
symptoms include fever, headaches, weakness, pruritus, lymphadenopathy, and in
some cases hepatosplenomegaly. In the second stage of the disease, sleeping
disorder is the primary symptom followed by neurological symptoms, such as various
movement and speech disorders [1]. This disease often also has the risk of being
misdiagnosed due to similarities with other fever-causing and neuropsychiatric
diseases/problems.
Diagnosing African sleeping sickness is a two-stage process: screening
followed by diagnostic confirmation [2]. The best test in terms of practicality and
speed to diagnose African sleeping sickness is by the card agglutination test for
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trypanosomiasis (CATT). This is a serological test that detects trypanosome-specific
antibody in blood, plasma, or serum and the agglutination reaction is then analyzed
visually [1, 4]. Other serological and molecular assays are available; however, they
are to be analyzed with caution due to lack of personnel training, laboratory testing
facilities, and poor accuracy and reproducibility [5]. Positive results from these
methods require further validation. The best method for confirmation is microscopic
examination of the lymph node aspirate, blood, or cerebral spinal fluid for the
presence of the parasite [1].
Development of a proper and viable treatment against the parasite has been
difficult and unfeasible due to the presence of approximately 2000 variant surface
glycoproteins (VSG) [1]. When infection initially occurs, the initial surface
glycoproteins are recognized by the host immune system, leading to the production
of appropriate antibodies. These antibodies are able to combat the presence of the
parasite; however, the parasite is simultaneously changing its surface glycoprotein,
so that it is no longer affected by the initial antibodies [6]. This cycle repeats itself
ultimately leading to the host’s immune system being unable to eliminate
trypanosome [7]. Currently there are five drugs that are routinely used against
African sleeping sickness: pentamidine and suramin are used to treat first-stage
disease, and melarsoprol, eflornithine, and nifurtimox are used to treat the secondstage disease [5]. Diagnosis and treatment using first-stage drugs as early as
possible are vital to increase the chance of a patient being cured. The drugs
effective against the second stage of the disease run a significantly higher risk of
toxic side effects, due to a greater level of complexity in administration, since it is
necessary for them to cross the blood-brain barrier [5].
Treatment for African sleeping sickness is variable based on the stage of the
disease and the subspecies that has infected the patient [8]. For T. b. gambiense,
pentamidine is effective in the first stage of disease and eflornithine in combination
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with nifurtimox is effective in the second stage of disease. For T. b. rhodesiense,
suramin is effective in the first stage of disease and melarsoprol is effective in the
second stage of disease.
For T. b. gambiense, the first choice of treatment is pentamidine [1, 5, 9].
Pentamidine is administered intramuscularly once daily over a span of 7 days, but
can also be given intravenously. if diluted in saline beforehand. When administered,
it is also followed by the administration of sugar, as hypoglycemia is one of the
adverse side effects of the drug. In addition, other effects include pain and swelling
at the injection site, hypotension, and gastrointestinal problems. Eflornithine is the
first choice of treatment for patients for whom the disease has progressed to the
second stage. More recently, eflornithine has been administered in combination with
a second drug called nifurtimox. This nifurtimox-eflornithine combination therapy
(NECT) has been shown to have higher cure rates along with lower fatality rates and
less severe adverse effects [5]. Eflornithine is given as a monotherapy if nifurtimox
is unavailable. With a complete NECT kit, nifurtimox is administered orally and
eflornithine is administered intravenously. In combination, nifurtimox is given to the
patient for ten days with three doses each day and eflornithine is given every twelve
hours. If only eflornithine is administered, four infusions are given daily for fourteen
days. For the NECT treatment, common side effects are abdominal pain, nausea,
and headaches, whereas when eflornithine is given as a monotherapy side effects
are more severe, leading to pruritus, diarrhea, myelosuppression, and even seizures
[1, 5, 9].
For T. b. rhodesiense, the first choice of treatment is the drug suramin [10].
Suramin rapidly deteriorates once it is diluted and needs to be administered to the
patient immediately intravenously. This drug is more complex to administer, since it
requires a schedule, that varies with each patient and can require treatments for up
to one month. In addition, it requires a test dose to avoid the risk of hypersensitivity
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reactions [5]. Adverse side for suramin effects are typically mild and reversible
including nephrotoxicity, neuropathy, agranulocytosis, and thrombocytopenia [1].
Melarsoprol is the final choice of treatment for patients who have progressed to the
second stage of the disease. Melarsoprol is the most toxic drug out of the five that
have been mentioned and is restricted to only be used for treating second stage T. b.
rhodesiense disease [11]. The most important severe side effect as a result of
melarsoprol treatment, administered intravenously every day for ten days, is an
encephalopathic syndrome that leads to the death in majority of patients who are
diagnosed with it. Patients are closely monitored to avoid progression of the
encephalopathic syndrome [1, 5].

1.2

dUTPase/Uracil in DNA
There are many different mechanisms by which DNA modifications can occur through

exogenous and endogenous damaging factors. One form of endogenous DNA modification is
the incorporation of uracil into DNA [12]. Uracil can appear in DNA through two different
methods, 1) cytosine deamination and 2) uracil incorporation into DNA instead of thymine
during DNA replication/repair [13].
The rate of cytosine deamination is greatly increased when DNA is single-stranded,
such as during DNA replication [14]. The newly incorporated uracil create premutagenic U:G
mispairs. This can result in a transition from C:G to T:A since DNA polymerase effectively and
efficiently incorporates adenine that pairs with the uracil and this is followed by the removal of
uracil and incorporation of thymine in its place [15-17]. It has been calculated that cytosine
deamination occurs in approximately 70 to 200 cytosine base pairs per day in every human cell
[17]. Cytosines in different forms, such as in cyclobutene dimers are deaminated faster than
other cytosines. Cytosine can also be deaminated enzymatically by enzymes, such as
activation-induced deaminase, which has been suggested to target C:G base pairs directly
[16].

5

The other source of uracil incorporation into DNA is through the normal function of
eukaryotic DNA polymerase [7]. Deoxyuridine triphosphate (dUTP) is incorporated into DNA
rather than deoxythymidine triphosphate (dTTP). DNA polymerases cannot distinguish between
uracil and thymine base pairs, therefore uracil is freely incorporated into DNA rather than the
appropriate thymine base pairs, depending on the available ratio of [dUTP/dTTP] (Figure 1)
[7]. This however, results in stable U:A base pairing, which are not mutagenic, in contrast to
the cytosine deamination which results in highly mutagenic U:G mispairs [18].

A
N
D

l
Po

DNA

DN

dUTP

A

Po
l

dTTP

dUTPase
(Dut1)
Thymidylate
Synthetase (TS)
dUMP

dTMP

Figure 1: Uracil (dUTP) can be incorporated into DNA.
Both dUTP and dTTP can be incorporated into DNA via DNA Polymerase. The presence of
dUTPase lowers [dUTP/dTTP] leading to greater synthesis of dTTP.
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The thymidine synthesis pathway is the only pathway for the synthesis of thymine to be
used during DNA replication via DNA polymerase [19]. Deoxyuridine triphosphate
diphosphatase (dUTPase), Dut1 in S. cerevisiae, is an essential enzyme that hydrolyzes dUTP
to deoxyuridine monophosphate (dUMP), a substrate for dTTP synthesis via other downstream
enzymes to be used for appropriate DNA replication. This regulates the extent of uracil being
incorporated into the DNA. Uracil in DNA is the cause of major mutations, in yeast, which
ultimately lead to thymine-less cell death (Figure 2) [20, 21]. This occurs due to the increased
[dUTP/dTTP] ratio, allowing for an increased direct incorporation by DNA polymerase.
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High dUTP:dTTP
U = Uracil
O = AP sites

DNA Replication
DNA polymerase

U

U
U

U

Uracil-DNA glycosylase
(Ung1)

O

O
O

O

Chromosome
fragmentation/
Cell death
Figure 2: Uracil-mediated DNA damage.
When uracil is incorporated into DNA, this activates the enzyme uracil DNA-glycosylase, which
removes uracil from DNA. This removal of uracil forms an AP site within in DNA and an
accumulation of these AP sites can lead to cell death due to DNA breaks.
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The mechanism to remove uracil from DNA utilizes the enzyme uracil DNA glycosylase,
Ung1 in S. cerevisiae [22]. When uracil is incorporated, Ung1 activates and removes uracil
from DNA resulting in the formation of a lesion called apurinic/apyrimidinic (AP) sites or abasic
sites. AP sites act to block DNA replication/repair machinery, leading to destructive outcomes,
such as single-strand and double-strand breaks, resulting in fragmentation and ultimately cell
death [13]. To prevent cell death, the base excision response (BER) pathway is initiated in
response to specific proteins, in this case uracil DNA glycosylase. Following the removal of
uracil and creation of AP sites, AP endonuclease proteins, such as APN1, incise the remaining
phosphodiester bonds generating 3’-hydroxyl and 5’-deoxyribose phosphate sections. The
5’deoxyribose phosphate end is removed by DNA deoxyribophosphodiesterase leading to the
single gaps being correctly filled in by DNA polymerase activity and further followed by DNA
ligase activity to restore DNA integrity [23]. Furthermore, the mechanism as to which uracil
DNA glycosylase-mediated repair is conducted varies with the initial position of uracil in the
DNA relative to the replication fork [16].
In the absence of Dut1, the frequency of uracil incorporation into DNA increases due to
the increase in [dUTP/dTTP] ratio, further increasing the activity of UNG1 leading to more AP
sites and eventually cell death, making Dut1 an essential enzyme [24]. All dUTPase enzymes
are essential enzymes in both eukaryotic and prokaryotic organisms, making this an excellent
protein/pathway to target with various dUTPase inhibiting small compounds, such as in T.
brucei [21]. In addition, sequence differences and structural differences in the dUTPase
enzyme also make it a desirable protein/pathway to target. The S. cerevisiae and human
dUTPase enzymes are both homo-trimers formed by beta-sheets and the T. brucei dUTPase
enzyme is a homo-dimer formed by alpha helices [24, 25].
The thymidine synthesis pathway is one of the most commonly targeted pathways used
to treat various types of cancer [11]. Downstream of dUTPase is the enzyme thymidylate
synthase (TS), which converts dUMP to dTMP using the methyl donor 5,10methyltetrahydrofolate (5,10-CH2 THF). This step is essential since dTMP is required for dTTP
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production, an essential precursor for DNA replication and repair. TS functions as a
homodimer, containing a substrate binding site for the nucleotide dUMP and a cofactor binding
pocket for 5,10-CH2 THF. The inhibition of TS can be achieved by blocking either of the two
sites. The substrate binding site can be blocked by nucleotide analogs and antifolates such as
5-fluorouracil (5-FU) and methotrexate (MTX), respectively [19, 26]. Any inhibition of TS leads
to the increase in uracil level ultimately leading to thymine-less death via the UNG1 mediated
repair pathway. dUTPase counteracts high levels of uracil, supplying additional pools of dUMP
for TS activity to generate dTMP. dUTPase levels and activity can directly influence the very
common TS-based treatment in many patients [19]. Further lowering the activity of dUTPase
along with a TS-based treatment can help treat cancer patients, increasing the chances of
success.

1.3

Auxin Inducible Degron System
Studying the consequences of null mutations is a very common and practical approach

to study the function of a gene product in vivo. However, in the case of essential genes
required for growth, these mutations must be conditional. Effective methods for studying
essential genes utilize constructing temperature-sensitive mutants or constructing mutants with
a regulatable promoter [27]. However, these two methods are problematic because
temperature sensitive mutants can laborious to generate and regulatable promoters can be
leaky. A relatively new method, the auxin-inducible degron (AID), is a technique that is able to
conditionally mutate a gene by degrading the target protein with no side effect in non-plant
eukaryotes. Indole-3-acetic acid (IAA), or auxin, is a plant hormone responsible for regulating
plant growth [28]. This compound is only found in plants, therefore when it is used in other
organisms such as S. cerevisiae, it can be concluded that any change resulting from addition of
AID is due to the presence of auxin. In budding yeast, the AID system has been successfully
applied to several proteins including Dut1. The AID system utilizes the SCF E3 ubiquitin ligase
complex in which auxin acts as the initiator to proteasome-mediated degradation [27, 29].
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Initially, the target gene is fused with an IAA transcriptional regulator, which acts as the degron
tag to induce degradation when auxin binds to it. This is followed by interaction with the F-box
protein, TIR1, part of the SCF complex, which contains the recognition domain. Once properly
recognized, the target protein is ubiquitylated via the E3 ubiquitin ligase, ultimately leading to its
degradation by the proteasome (Figure 3).

TIR1
AID

Dut1

SCF
Auxin

TIR1
AID

Dut1

SCF
Ubiquitylation

E3

Degradation
Figure 3: Auxin inducible degron system.
The addition of auxin to the culture medium among non-plant organisms, modified with degron
tag and TIR1 F-box protein, allows for the rapid degradation of a protein of interest. Firstly,
auxin binds to the degron tag, which then allows for the interaction with the TIR1, part of the
whole SCF complex. The target protein is then ubiquitylated by E3 ubiquitin ligase, ultimately
leading to its degradation by the proteasome.
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Papagiannakis et al., (2017) have more recently demonstrated the effectiveness of the
AID system, easily applying it to S. cerevisiae [29]. Utilizing the ubiquitin-mediated protein
degradation system along with AID system, they were able to eliminate essential proteins of
interest and create conditional mutants. The two genes they targeted were Cdc28 and Cdc14,
both essential cell cycle proteins. Upon the addition of 0.1 mM auxin, they were able to show
the AID system efficiently depleted the two cell-cycle proteins.

1.4

Schrödinger’s Virtual Drug Screen
The conventional method for drug screening is known as high-throughput screening

(HTS) [30, 31]. Specifically, for structure-based drug design, a vast number of molecules are
each subjected to a reaction in the presence of a target protein, cell, etc. Depending on the
assay, observational changes are then measured either by machine or manually to determine
the effectiveness of the molecules being tested. This process, however, is very tedious, time
consuming, and not cost effective considering that simply finding a potential candidate in a drug
screen is only a starting point [32]. The advancements in technology has opened new
possibilities for computer-aided drug discovery tools for a faster and more cost-efficient
method, otherwise known as virtual screening [33].
Schrödinger is an emerging company in the field of biotechnology. Schrödinger offers a
suite of programs that allow in silico simulation of molecular docking. This is achieved by using
their physics-based computational platform, which allows users to evaluate a large selection of
online available molecules to search for solutions through interactive and predictive modeling,
molecule design, and molecular simulations. Glide is one of the programs in the Schrödinger
suite, which allows for studying ligand-receptor docking [34]. For structure-based drug design,
any protein structure can be uploaded to the software, if crystal structures are available. These
structures can then be further prepared to simulate an active enzyme, for example adding a
magnesium cofactor to a human dUTPase protein. A large database of ligands can then be run
against the protein structure’s active site with the software calculating multiple thermodynamic
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variables. Two of these variables, docking score and binding energy, indicate how well the
ligand fits into the protein’s active site and how strongly the ligand binds, respectively.
Computational docking is becoming a widespread norm in the field of pharmaceuticals
and biotechnology due to the programs high-throughput screening capability. This allows for a
plethora of compounds to be screened for biological activity. With crystal structures available
for all varieties of proteins, Schrödinger’s virtual drug screening program allows the user to
upload the structure to be studied, allowing for discovery at a much-accelerated rate. The
uploaded protein structure can be modified to allow for a better suited structure-based drug
design. Glide offers a range of screening modes, each with a varying screening speed and
accuracy hits: high-throughput virtual screening (HTVS) is the fastest screening method to
easily screen through millions of ligands, standard precision (SP) screens through thousands of
ligands, and lastly extra precision (XP) screens through dozens to hundreds of ligands with the
best accuracy scoring. Overall, Schrödinger’s Glide allows for the user to achieve faster and
more accurate drug design, dramatically reducing research and development costs and
increasing productivity.
The combination of model organism-based genetic approach and virtual drug
screening allows for a comprehensive inquiry of potential drugs and small molecules
for a specific target. Structural differences in essential enzymes, such as dUTPase,
in various organisms ranging from humans to trypanosomes brings forth the
question: can a molecule be found that is toxic to one but not to the other? This
study explores both an organism model and virtual drug screening in order to
address this question. Specifically, such combinatorial approaches will be used to
search for a molecule toxic to the pathogenic parasite T. brucei and not to the human
host. Furthermore, this opens a pathway to a more cost-and time-efficient
pharmacological strategy to be able to combat against various infectious diseases
such as African sleeping sickness.
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Chapter 2: Materials and Methods
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2.1

Plasmids and Yeast Strains
The plasmids and yeast strains used for this project are listed in Table 1.

Table 1: Plasmids and Yeast Strains
Plasmids

Description

Origin

pNK14

vector pRS426

Previous
study

pNK57

vector p426GAL1

Previous
study

pNK258

yDUT1-3xHA; BamHI (5') and EcoRI (3')

This study

pNK259

hDUT-3xHA; BamHI (5') and EcoRI (3')

This study

pNK260

tbdUTPase-3xHA; BamHI (5') and EcoRI (3')

This study

pNK264

pGal-yDUT1-3xHA; BamHI-EcoRI fragment from
PNK258 cloned into PNK57

This study

pNK265

pGal-hDUT-3xHA; BamHI-EcoRI fragment from
PNK259 cloned into PNK57

This study

pNK266

pGal-tbdUTPase-3xHA; BamHI-EcoRI fragment from
PNK260 cloned into PNK57

This study

pNK285
pNK286

HO(SacI)-pGal-hDUT-URA3-HO(MfeI); flanked
hDUT expression cassette with restriction sites SacI
and MfeI along with HO locus sequence
HO(SacI)-pGal-tbdUTPase-URA3-HO(MfeI); flanked
tbdUTPase expression cassette with restriction sites
SacI and MfeI along with HO locus sequence

This study
This study

pNK290

removed portion of tbdUTPase gene in PNK286 with
restriction enzyme SpeI

This study

pNK296

pET22b (+)-yDUT1

Addgene;
Plasmid
#12667

pNK297

PNK296 transformed into BL21(DE3) competent
cells

This study

pNK301

yDUT1 removed via restriction enzymes NdeI and
XhoI; ligated hDUT gene via PCR

This study

pNK303

PNK301 transformed into BL21(DE3) competent
cells

This study
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Table 1. Cont.
Plasmids

Description

Origin

pNK304

yDUT1 removed via restriction enzymes NdeI and
XhoI; ligated tbdUTPase gene via PCR

This study

pNK305

PNK304 transformed into BL21(DE3) competent
cells

This study

pNK306

PNK14 transformed into BL21(DE3) competent cells

This study

pNK224

pGPD2

Addgene;
Plasmid
#43972

Yeast Strains

Description

Origin

YNK355

-LEU strain

Previous
study

YNK421

WT yDUT1; AFB2 gene integrated into ADE2 locus

This study

YNK425

auxin inducible degron (AID) 6xFLAG tag added to 3'
end of yDUT1 in YNK421

This study

YNK679

ung1Δ in YNK425

This study

YNK684

URA3 marker; ung1Δ loxed-out

This study

YNK756
YNK757
YNK760

hDUT expression cassette integrated into HO locus
of YNK425 under the control of pGal promoter with
URA3 marker
tbdUTPase expression cassette integrated into HO
locus of YNK425 under the control of pGal promoter
with URA3 marker
inactive tbdUTPase expression cassette integrated
into HO locus of YNK425 under the control of pGal
promoter with URA3 marker

This study
This study
This study

YNK766

URA3 marker removed from YNK756

This study

YNK767

URA3 marker removed from YNK757

This study

YNK769

URA3 marker removed from YNK760

This study

16

2.2

Auxin Growth Assays
All yeast growth was performed at 30°C. To determine viable cells by the CFU

assay, strains YNK421, YNK425, and YNK355 were streaked out on to agar plates
containing yeast extract, peptone, and 2% dextrose (YEPD) and overnight 1mL
overnight cultures were grown in liquid YEPD as well. For YNK355, 5 mL cultures in
YEPD were grown. From the overnight cultures for YNK421 and YNK425, subcultures were made by adding 20 µL to 1 mL YEPD containing auxin (EtOH soluble
auxin: Spectrum Chemicals; IN125 and H 2 O soluble auxin: Sigma-Aldrich, I5148) at
concentrations of 0, 5, 50, and 100 µM. YNK355 cells were left growing in 30°C.
After 24 hours, YNK421 and YNK425 cells were centrifuged and collected in 1.5 mL
micro-centrifuge tubes, washed with 1 mL H 2 O, centrifuged again and resuspended
in 200 µL of H 2 O. For YNK355, 5 mL cultures were collected in 50 mL tubes and
centrifuged at 3000 x g for 5 minutes and washed and resuspended in 50 mL of H 2 O.
YNK421 and YNK425 cells were diluted by a factor of 1x10 6 in YNK355 cell solution
and plated on agar plates containing synthetic dextrose LEU dropped out (SD-LEU).
THE CFU were counted after 4 days of growth and survival percentages were
calculated.
For the spot growth assay, strains YNK421 and YNK425 were streaked out on
YEPD and colonies on YEPD plates were used to inoculate overnight cultures in
YEPD. Overnight cultures were diluted to an OD 600nm of 1 (approximately 5x10 7
cells/mL) and serial dilutions were made ranging from 1x10 6 to 1x10 3 cells/mL. The
dilutions (5 µL) were spotted on YEPD plates containing auxin (0, 50, 100, 500 uM)
and incubated at 30°C for 24 hrs.

2.3

Auxin Growth Curves
Growth curves were created by measuring absorbance on the BioTek Synergy

plate reader at a wavelength of 600 nm. All readings were performed for 18 to 24
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hours. From overnight cultures, 100 µL was added to 5mL of media and incubated
again until OD 600nm reached 0.6 to 0.8 and then diluted 0.1 at a final volume of 200
µL within the 96-well plate. The following auxin [ethanol/water soluble]
concentrations were used, diluted using either YEPD media or YEP-GE [YEP-GE
composition with and without galactose]: 0, 5, 50, and 500 µM. 5-fluorouracil (5-FU)
was also used with auxin at the concentration of 25 µM for specific treatment
targeting the thymidine synthesis pathway.

2.4

High Throughput Virtual Screen using Schrödinger’s suite.
High throughput virtual screening (HTVS) was performed using Schrödinger’s

Glide software. For the three-dimensional (3D) crystal structure of T. brucei dUTPase,
the 1.47 Å resolution T. brucei dUTPase structure (PDB ID: 4DK2) and (PDB ID:4DL8) [25]
with the “Search Space” defined as the annotated catalytic center where dUTP/dUMP binds
were used. For the docking simulation of the human DUT enzyme, the annotated
structures from the PDB database were used (PDB ID: IQ5U and 3ARA) [35, 36]. A custom
library of 5000 compounds (“Tainer 5000”) selected from the Life Chemical library for their
variety, low toxicity, and drug-like properties according to the Lipinski’s rules was used as the
ligand library [37]. Compounds were first screened for docking into the tbdUTPase
and hDUT structures’ active site.

2.5

T. brucei/Yeast Growth Curves
The 13 molecules identified through HTVS were provided by Dr. John Tainer

from MD Anderson Cancer Center. The strain YNK421 was cultured in YEPD media
in a 96-well plate at a volume of 200 µL with the starting OD 600nm of 0.1 with
absorbance readings recorded at a wavelength of 600nm on the BioTek Synergy
Plate Reader. OD 600nm readings were taken every 15 minutes for 20 hours. The final
concentration for each of the 13 molecules was 10 µM and methotrexate (MTX) was

18

used as a negative control at a final concentration of 500 µM. All samples tested
contained DMSO at final concentration of 0.5% v/v.
The T. brucei growth assay was performed under the supervision of Dr. Kyu
Joon Lee, a postdoc in the lab of Dr. Ziyin Li from McGovern Medical School,
UTHealth. A stock of T. brucei blood-stream form (bsf) was cultured in HMI-9
medium supplemented with 10% fetal bovine serum at 37°C with 5% CO 2 , in a sterile
culture bottle and the medium was replenished every 2 days. To test the effect of the
13 molecules, the stock culture was diluted down to an initial target concentration of
5x10 4 cells/mL by counting cells using a hemocytometer. Experimental cultures were
made in 48-well culture plates at a final volume of 200 µL. Each of the 13 molecules
were added to different wells with MTX serving as the negative control. All the
compounds were at the final concentration of 10 µM and contained DMSO at a final
concentration of 0.5% v/v. Cultures were grown for 4 days and 10 µL of cells were
removed and counted using a hemocytometer every 24 hours.

2.6

Protein Purification
Expression vector pET22b (+)-yDUT1 with 6X affinity His-tag was acquired

from Addgene (plasmid #12667). The plasmid was purified using QIAprep Spin
Miniprep Kit and transformed into BL21(DE3) competent cells for overexpression.
For cloning of hDUT and tbdUTPase sequences, pET22b (+)-yDUT1 was first cut
with NdeI and XhoI to remove the yDUT1 sequence. The hDUT sequence was PCR
amplified using F primer: TAAGCACATATGCCATGTAGTGAAGAGAC and R primer:
TGCTTACTCGAGATTTTTGCCGGTACTACC. The tbdUTPase sequence was PCR
amplified using F Primer: TAAGCACATATGAAAAACGCGCGTCGTG and R primer:
TGCTTACTCGAGACTCTTCAACCAGTGACC. The amplified PCR products were
ligated to NdeI/XhoI cut pET22b (+)-yDUT1. Both ligations were confirmed by
sequencing (Eurofins Scientific) using T7 and T7term primers, followed by
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transformation into BL21(DE3) cells for overexpression. For a negative control,
empty vector pRS426 was transformed into BL21(DE3) competent cells.

Protein purification was performed as described previously in Dabrowski and
Ahring (2003), [38], with some modification as described below. All four BL21(DE3)
cell types were grown overnight in 5 mL of LB-ampicillin. Subcultures were then
started in 500 mL of LB-Ampicillin-0.1% Glucose media and growth was monitored
until an OD 600nm of 0.3-0.5 was reached. IPTG was added at a final concentration of
0.5 mM and cultures were grown for an additional 4 hours. The cells were harvested
by centrifugation at 4,000 x g for 10 minutes at 4°C and the supernatant was
removed, and the cells were stored in -80°C. Overexpression was confirmed by
collecting cells before and after IPTG induction and Western immunoblotting was
performed on the whole cell extracts. Thawed frozen cells were resuspended in 20
mL of Buffer A (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 5 mM Imidazole, 0.1% Triton
X-100, Protease Inhibitor Cocktail II, EDTA Free (10X)) and then sonicated for a total
of 12 minutes (2 seconds on/off). They were then centrifuged at 18,000 x g for 20
minutes at 4°C and lysate was collected along with a small 50µL aliquot and stored
in 4°C. 2 mL of HisPur Ni-NTA Resin (Thermo Scientific, Prod # 88221) was added
to the cell lysate and mixed overnight at 4°C. The column for protein purification was
set up and lysates containing Ni-NTA resin was added to the column and the flow
through was collected. Small 50 µL aliquots were collected from the flow through as
well. The Ni-NTA resin was washed with 30 mL of Buffer A-50 (Buffer A with 50 mM
imidazole) and 30 mL of Buffer A-80 (Buffer A with 80 mM imidazole) and lastly
eluted with 10 mL of Elution Buffer (Buffer A with 500 mM imidazole). 50 µL aliquots
also collected after the two wash steps and the elution was collected in 1 mL
aliquots. The purity was checked by electrophoresis of all collected aliquots and
elution through a Novex WedgeWell 4-20% Tris-Glycine Gel (Thermo Scientific) and

20

staining with EZ-RUN Protein Gel Staining Solution (Fisher Scientific, Prod #
BP3620-1). Elution tubes 7-10 were combined and desalted with an Amicon Ultra-4
10K Centrifugal Filter (Millipore, Prod # UFC801008). Then the purified protein was
resuspended in Storage Buffer (20 mM Tris-HCl pH 8.0, 50 mM KCl, 50% Glycerol,
0.5 mM PMSF) and stored at -80°C until it was ready for use. Protein quantification
was performed via QuantiChrom Protein Assay Kit (BioAssay Systems, Prod #
QCPR-500) with BSA as a standard.

2.7

Western Immunoblotting
dUTPase protein levels were visualized by Western immunoblot of the crude

cell lysates. Cells were first adjusted to an appropriate OD 600nm and the cell pellets
were resuspended in 100 µL of dH 2 O and 100 µL of 0.2 M NaOH and incubated at
room temperature for 5 minutes. Cells were centrifuged and resuspended in 50 µL of
SDS sample buffer and heated for 5 minutes at 95°C. All samples and the protein
ladder (Xpert 2 Prestained Protein Marker) were loaded in volumes of 10 µL in
Novex WedgeWell 10% Tris-Glycine Gel and initially run at 90 V for 10 minutes
followed by 150 V for 30 minutes in SDS Running Buffer. The proteins were
transferred from the gels to PVDF Membrane using Semi-Dry Transfer. All
membranes were blocked with 5% milk in 1X TBS + 0.1% Tween overnight at 4°C.
The primary and secondary antibody treatments were also performed overnight at
4°C. Anti-Flag antibody treatment did not require a secondary antibody treatment,
since it was conjugated with horseradish peroxidase (HRP). Anti-Nsr1 and Anti-His
antibody treatments required a secondary antibody treatment of Anti-Mouse-HRP.
For blot visualization, blots were treated with West-Q Femto ECL Solution for 3
minutes and then imaged on Bio-Rad ChemiDoc MP Imaging System.
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2.8

Pyrophosphate-based Enzymatic Activity
Enzymatic activity was measured using the PiPer Pyrophosphate Assay Kit’s

“Measuring Enzymatic Activity” protocol (Thermo Scientific, Prod # P22062). For the
three purified proteins, yDut1, hDUT, tbdUTPase, and our vector control, 500 ng was
used for each purification and dUTP was used at a concentration of 0.5 mM.
Fluorescence was measured using the BioTek Synergy Plate Reader at excitation
and emission wavelengths of 575/15 and 620/15 nm respectively. Readings were
recorded everyone and a half minutes for one hour at a temperature of 37°C.

2.9

PCR-based Enzymatic Activity
A mix of individual dATP, dCTP, and dGTP and either dTTP or dUTP were

utilized for PCR reactions. 5 µL of 5 mM dUTP or dTTP were incubated for 24 hours
at 37°C with 5 µL of each purified protein; yDut1, hDUT, tbdUTPase, and vector
control in 10 µL of reaction buffer (100 mM Tris-HCl pH 7.5, 20 mM MgCl 2 , 20 mM
DTT, and 0.2 mg/mL BSA). The reactions were stopped by freezing and storing
samples at -20°C. PCR reactions were set up utilizing Taq DNA Polymerase (Fisher
Scientific, Prod # FB-5000-50) and MyTaq DNA Polymerase (Bioline, Prod # BIO21105) using the reaction concentrations according to the manufacturer’s
recommendations. In place of a dNTP mix, dUTP or dTTP treated with yDut1, hDUT,
tbdUTPase, or the vector control was added to the mix of dATP, dCTP, dGTP at 2
mM each. PCR cycles were set as follows: 1 cycle of 95°C for 5 minutes, 35 cycles
of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute,1 cycle of 72°C
for 7 minutes, and hold at 4°C. PCR products were separated on 1% agarose gels
and visualized using the Bio-Rad ChemiDoc MP Imaging System.
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Chapter 3: Results
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3.1

Auxin growth assay/curves showing growth inhibition in the presence of
auxin
The overall objective of this project was to discover a small molecule that

binds and inhibits the function of T. brucei dUTPase but has no effect on human DUT
or yeast Dut1. Since the dUTPase enzyme is essential for cell viability in T. brucei as
well as in humans, a small molecule with such discriminatory properties will have a
great potential as an anti-parasitic drug to combat African sleeping sickness. To
accomplish this goal, I proposed: 1) to determine if the dUTPase proteins from
human and T. brucei can functionally complement the absence of Dut1 in S.
cerevisiae, and 2) to discover and characterize a list of possible small molecules that
inhibit the function of T. brucei dUTPase.
As described in Chapter 1, the dUTPase enzyme is essential in all organisms,
making it an excellent target for a small molecule to bind to and inhibit its function,
ultimately killing its host organism. Being able to use yeast a model system to
express human and T. brucei dUTPase genes would allow us to screen for a drug or
small molecule and achieve our overall objective. I hypothesize that this is possible
due to the differences in protein structure of T. brucei and human/yeast dUTPases
(Figure 4).
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B

A

S. cerevisiae dUTPase
(Dut1)

Human dUTPase
(Dut)

C

T. brucei dUTPase
(tbdUTPase)
Figure 4: dUTPase crystal structures.
(A)yDut1 [24], (B)hDUT [35], and (C)tbdUTPase [25] 3D crystal structures. yDut1
and hDUT are homo-trimers formed by beta-sheets, whereas tbdUTPase is a homodimer formed by alpha-helices.
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Furthermore, because dUTPase is essential, conventional null mutation
methods are not feasible to study this enzyme. Here, I used in the budding yeast, S.
cerevisiae, a conditional knockdown method known as the auxin inducible degron
(AID) system. The strain YNK425, which contains the DUT1 gene with C-terminally
located AID-tag (ydut1-AID), was created by a previous lab member, Dr. Norah Owiti.
This allows us to utilize the AID system to knockdown the dUTPase enzyme in the
presence of auxin. The effectiveness of the AID system was shown in numerous
ways. First, a simple CFU assay was performed to show that in the presence of
auxin at a concentration of 5 and 50 µM, the survival rate for YNK425 is reduced in
comparison to two isolates of YNK421 (WT yDUT1) (Table 2). Survival rates were
calculated relative to the cultures grown without auxin. Overall, auxin does not inhibit
the growth of YNK421, but does indeed inhibit the growth of YNK425. Cell growth
was maximally inhibited when cells are grown in the presence of 50 µM auxin.
Although there are some cultures/replicates that had a high survival rate for YNK425,
similar to when treated without auxin, the overall trend remained the same where the
strain’s survival decreased in the presence of auxin. These replicates with outlying
results may be the result of suppressor mutations arising during overnight growth.
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Table 2: CFU Assay showing survival rates of WT yDUT1 and ydut1-AID.
Auxin
Plate 1
Plate 2
Total
Survival
Strain
Concentration
Count
Count
Count
Rate
WT DUT1
145
186
331
98%

5 µM

50 µM

WT DUT1

212

151

363

86%

WT DUT1

185

174

359

114%

WT DUT1

209

177

386

97%

WT DUT1

140

162

302

78%

WT DUT1

166

142

308

87%

ydut1-AID

188

179

367

120%

ydut1-AID

12

9

21

58%

ydut1-AID

5

15

20

91%

ydut1-AID

42

38

80

29%

ydut1-AID

50

47

97

41%

ydut1-AID

41

40

81

30%

WT DUT1

161

158

319

95%

WT DUT1

198

195

393

93%

WT DUT1

137

179

316

100%

WT DUT1

162

175

337

84%

WT DUT1

165

214

379

98%

WT DUT1

184

201

385

108%

ydut1-AID

152

152

304

99%

ydut1-AID

2

2

4

11%

ydut1-AID

1

5

6

27%

ydut1-AID

9

15

24

9%

ydut1-AID

38

46

84

35%

ydut1-AID

14

21

35

13%

27

To further show that the AID system is functioning properly, the strain YNK684
(ydut1-AID ung1Δ) was also grown in the presence and absence of auxin. In YNK684 the,
UNG1 gene encoding the uracil DNA glycosylase is deleted, thus the uracil in the DNA is no
longer removed and AP sites are not generated. Therefore, it is expected that in YNK684, the
increase in the level of uracil in DNA when Dut1 is degraded by auxin would have less effect.
YNK684 was grown and treated with 50 µM or 100 µM auxin and subjected to the CFU assay
(Table 3). Survival rates were calculated relative to the cultures grown without auxin. As can be
seen in the table, all replicates for both isolates for YNK684 show a high survival rate in the
presence of both 50 µM and 100 µM auxin, whereas YNK425 shows a low survival rate for both
auxin concentrations. For both strains there are replicates that are outliers and do not follow the
expected trend for their respective strains, which again is most likely due
to suppressor mutations. However, for YNK684, where a 56.00% survival rate is seen for
YNK684 in 100 µM auxin, the outliers may be due to technical errors when preparing cultures
resulting in low colonies formed. The dashes in the table represent no colonies were grown in
the plate. Therefore, in the cases in which one of the plates did not have any colonies, the
number of colonies grown on the other plate was doubled to calculate the survival rate.
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Table 3: Auxin CFU Assay showing survival rates for YNK425 and YNK684.
Auxin
Concentration

50 uM Auxin

100 uM Auxin

ydut1-AID

Plate 1
Count
-

Plate 2
Count
7

Total
Count
14

ydut1-AID

15

20

35

16.36%

ydut1-AID

9

5

14

5.17%

ydut1-AID

24

24

48

21.05%

ydut1-AID

14

6

20

8.20%

ydut1-AID

23

23

46

22.01%

ydut1-AID

9

9

18

7.76%

ydut1-AID

106

89

195

87.05%

ydut1-AID

21

5

26

13.27%

ydut1-AID

22

17

39

18.57%

ydut1-AID ung1Δ

76

108

184

88.46%

ydut1-AID ung1Δ

125

68

193

96.50%

ydut1-AID ung1Δ

108

109

217

93.94%

ydut1-AID ung1Δ

113

101

214

91.45%

ydut1-AID ung1Δ

154

112

266

105.14%

ydut1-AID ung1Δ

118

118

236

112.38%

ydut1-AID ung1Δ

141

107

248

124.00%

ydut1-AID ung1Δ

99

96

195

100.00%

ydut1-AID ung1Δ

154

117

271

115.81%

ydut1-AID ung1Δ

106

88

194

79.51%

ydut1-AID

5

11

16

7.69%

ydut1-AID

9

22

31

14.49%

ydut1-AID

7

15

22

8.12%

ydut1-AID

18

21

39

17.11%

ydut1-AID

16

9

25

10.25%

ydut1-AID

13

18

31

14.83%

ydut1-AID

18

14

32

13.79%

ydut1-AID

115

87

202

90.18%

ydut1-AID

11

9

20

10.20%

ydut1-AID

23

17

40

19.05%

ydut1-AID ung1Δ

89

114

203

97.60%

ydut1-AID ung1Δ

95

98

193

96.50%

ydut1-AID ung1Δ

88

81

169

73.16%

ydut1-AID ung1Δ

106

84

190

81.20%

ydut1-AID ung1Δ

94

112

206

81.42%

ydut1-AID ung1Δ

-

102

204

97.14%

ydut1-AID ung1Δ

56

56

112

56.00%

ydut1-AID ung1Δ

111

74

185

94.87%

ydut1-AID ung1Δ

120

108

228

97.44%

ydut1-AID ung1Δ

-

123

246

100.82%

Strain

“-“ represent no colonies were grown
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Survival Rate
6.73%

The CFU assay shows that the AID system in the strain YNK425 is functional
and effective in conditionally knocking down the essential enzyme Dut1 in S.
cerevisiae. However, due to inconsistencies with the CFU assay in terms of colony
counting and survival rates, the effectiveness of the AID system in YNK425 was also
examined using the spot growth assay (Figure 5) and growth curves determined by
using a plate reader (Figure 6). In Figure 5, four different auxin concentrations were
tested on YEPD plates; 0, 50, 100, and 500 µM. The growth of ydut1-AID-containing
YNK425 is significantly inhibited as the auxin concentration increases due to the
presence of the AID system causing the degradation of yDUT1. Conversely, the wildtype yDUT1-containing strain YNK421 shows no reduction in growth under any of the
auxin concentrations. The smeared culture on the 0 µM auxin plate for YNK425 was
due to a pipetting error. Figure 6 also includes the strain YNK679 (ydut1-AID-ung1Δ),
which is expected to show no signs of growth inhibition, because although grown in the
presence of auxin, AP sites do not form due to the absence of UNG1. The growth curves
shown in Figure 6 consist of YNK421, YNK425, and YNK679 incubated in YEPD and at three
different auxin concentrations (0, 50, and 500 µM). When YNK425 is treated with 50 µM or 500
µM auxin, there is a significant inhibition in the growth rate in comparison to when YNK425 is
not treated with auxin. In addition, YNK421 and YNK679 grow to a saturation point as expected
with and without auxin. It can be noted that YNK425 does not grow as well as the other two
strains even in absence of auxin. This may be because the AID-tag may slightly interfere with
Dut1 function.
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50 µM

100 µM

500 µM

WT yDUT1

ydut1-AID

WT yDUT1

ydut1-AID

0 µM

Figure 5: Spot growth assay with and without auxin.
Cultures for strains ydut1-AID and WT yDUT1 were serially diluted and spotted on
YEPD plates containing 0 µM (top left), 50 µM (top right), 100 µM (bottom left), and
500 µM (bottom right) auxin.
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1.2
YNK421 0μM

1

YNK421 50μM
OD600

0.8

YNK421 500μM
YNK425 0μM

0.6

YNK425 50μM
YNK425 500μM

0.4

YNK679 0μM
0.2

YNK679 50μM
YNK679 500μM

0
0

2

4

6

8
10
12
Time (hours)

14

16

18

Figure 6: Growth curves showing effectiveness of AID system.
OD 600nm measurements over indicated time in hours for YNK421, YNK425, and
YNK679 in the presence of 0, 50, and 500 µM auxin in YEPD media utilizing BioTek
plate reader. N = 8 for each strain and auxin condition.
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After observing growth inhibition of YNK425 in the presence of auxin, we next
wanted to confirm the AID system’s specificity and visually demonstrate the auxindependent degradation of the Dut1 protein. Since the Dut1 protein is 3X-Flag tagged
in addition to the AID tag in YNK425, visualization of its degradation in the presence
of auxin is made possible using Western immunoblotting with anti-Flag antibody.
Subcultures of YNK425 were started and initially grown for 4 hours before adding
auxin to have an equal Dut1 expression level for cultures treated with and without
50µM auxin. Growth measurements at OD 600nm were also recorded to ensure the
same number of cells were loaded onto the gels for each timepoint to track the
degradation of Dut1 in the strain YNK425 (Figure 7). Cells were collected and
extracts were prepared at 0, 2, and 6 hour timepoints. It can be clearly seen that
after 2 hrs of treatment with 50 µM auxin, the amount of Dut1 protein is greatly
reduced, but recovers at 6 hours. Without any auxin, the expression of Dut1 does not
change significantly over the time examined.
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Time (hours)

0

2

6

0

2

6

ydut1-AID
(!-Flag)
NSR1
(!-Nsr1)
0 µM Auxin

50 µM Auxin

Figure 7: Degradation of Dut1 in YNK425.
Cell extracts were collected at 0, 2, and 6 hour timepoints to create a western blot
showing the degradation of Dut1 when treated without auxin (left) or with 50 µM
auxin (right). 3X-Flag tagged ydut1-AID was detected using anti-Flag antibody. AntiNsr1 antibody was used as a loading control.
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The auxin CFU assay, spot growth assay, and growth curves that have been
presented all prove that the AID system is indeed functional in the strain YNK425
and effectively degrades the dUTPase protein in the thymidine synthesis pathway.
Since this pathway is heavily targeted by well-studied molecules such as 5-FU
(Figure 8A), we then sought to see how YNK425 behaves in the presence of auxin
as well as 5-FU. This experiment was conducted to determine whether the
combination of 5-FU and auxin would have a synergistic effect on the cell growth in
YNK425 due to an increase in [dUTP/dTTP] (Figure 8B). This was tested with
another growth curve analysis using a plate reader. The auxin concentrations used
for this were 0, 5, and 500 µM along with and without 25 µM 5-FU. Initially, 10 µM of
5-FU was used, but the difference in cell growth was less than significant (data not
shown). It can be seen that when 25 µM 5-FU is added to 0 µM and 5 µM auxin, you
do see an additive effect in cell growth inhibition is observed. However, at 500 µM
auxin there is less cell growth with 5-FU added, but the difference is too small to
make any significant conclusion. Overall, it can be stated that auxin in combination
with 5-FU does help with inhibiting cell growth in the strain YNK425.
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Figure 8: dTTP synthesis pathway and the targets of auxin, 5-FU, and MTX.
(A)5-FU and MTX are well known drugs that target thymidylate synthetase and
dihydrofolate reductase, respectively, in the thymidine synthesis pathway. (B)
Growth curve of YNK425 with and without auxin and 25 µM 5-FU, grown in YEP-GE
2% galactose media.

36

3.2 Expression of human and T. brucei dUTPase in yeast
With the overall objective being to discover a small molecule that inhibits
tbdUTPase, next I tested if dUTPase genes from yeast, human, and T. brucei on
plasmids under a galactose inducible promoter could be transformed into YNK425
and compliment the low level of dUTPase when the native Dut1 protein is
conditionally knocked down in the presence of auxin. Table 4 below shows the
sequences used for yeast, human, and T. brucei dUTPase genes. The sequences
also contain a HA tag which allowed for their expression to be confirmed. This was
performed by a previous graduate student, Dr. Norah Owiti. The plasmid structure
containing dUTPase genes is shown in Figure 9.

37

Table 4: dUTPase gene sequences for yeast, human, and T. brucei

yDUT1
(PNK264)

hDUT
(PNK265)

tbdUTPase
(PNK266)

ATGACTGCTACTAGCGACAAAGTACTAAAGATTCAATTGCGCTCAGCAAGCGC
TACTGTACCTACCAAAGGTTCTGCCACTGCCGCGGGATACGACATTTATGCAT
CTCAGGATATTACCATTCCGGCTATGGGTCAAGGTATGGTTTCCACCGACATAT
CGTTCACCGTACCTGTTGGTACCTACGGTCGTATTGCGCCAAGGTCAGGCCTG
GCAGTGAAAAACGGTATCCAAACCGGTGCTGGTGTTGTCGACAGAGATTACAC
CGGTGAAGTTAAAGTAGTTTTATTCAATCATTCACAGAGGGATTTCGCGATCAA
AAAAGGTGATCGCGTAGCCCAATTGATTCTGGAAAAAATTGTCGATGATGCCC
AGATCGTTGTTGTAGACTCTCTGGAAGAAAGTGCAAGAGGGGCCGGTGGCTTT
GGTAGCACTGGTAAC
ATGCCATGTAGTGAAGAGACTCCGGCTATTTCTCCGAGTAAGAGAGCGAGGCC
CGCTGAGGTGGGTGGAATGCAACTACGTTTCGCCAGATTGAGTGAACATGCAA
CGGCCCCTACTAGAGGTAGTGCCAGGGCTGCCGGGTATGACCTGTACTCAGC
GTATGATTATACGATCCCCCCCATGGAAAAAGCTGTTGTAAAGACCGATATTCA
AATTGCCCTGCCCTCTGGCTGCTACGGAAGGGTAGCTCCCAGAAGTGGGCTT
GCCGCTAAGCACTTCATAGATGTGGGAGCAGGAGTAATTGATGAGGATTATCG
TGGCAACGTGGGAGTAGTCTTGTTTAACTTTGGTAAGGAGAAATTCGAGGTGA
AAAAAGGGGATAGAATAGCGCAGTTGATTTGTGAAAGAATCTTCTATCCTGAAA
TCGAGGAAGTCCAGGCCCTTGACGACACGGAGAGGGGTAGCGGTGGATTTGG
TAGTACCGGCAAAAAT
ATGAAAAACGCGCGTCGTGTGTCCCTAAGCCCCCTAATTTTAAGGAGCCTTGC
CGAGTTGCAAGATGGACTTAATACCGTGGTAGATAAAAACTGGAGACAGTTGA
GGAGACCAGGTGACTGGTCCTTGGCCATCACTATGGAGGCAGCAGAATTGCTT
GACAGCTATCCGTGGAAGTGGTGGAAAAATGTAAAGGCGCAACCCGATTTGCA
GAACGTAAAGATTGAGCTGACCGACATCCTTCACTTTTCTCTTAGCGGGGCAAT
GCAGGTCTCTGATGAGAACAGTGGAGCCGTGCACAAGGCAGAGGCTGGCTCC
AATGGGGAGTCAGGAAAACATTGGTGTTATTTCGACCAGCCAAGAGCGTTGCC
CGCCGCGGGCGGCGCGGAATATGTCGCGTGCGTTGAAACACCTGGCTCATCA
TTGAGCGCACCAGTCAGTGCAGACGAGTGCGACCTGGCGGACTTCATGTTCTT
CCCGCTGAGTGATACTAATAATGCACTAGCCTCTTTCCAAAATATAATCAGACT
GGCCTCATTACAAAGATTTCAACTAGTAACATCTGCTGTTATTGCAGCGGCGGA
TGACATTGGGTTTAATCTGGTCGCCTACTATGTAGCTAAACATACGTTGAACGG
CATTCGTCAGATGAAGGGCTATAAGGATGGAACCTACGTCAAGGTACAAAAAG
GTGTTGAAGATAATGAGTTACTTCACGGGTGCATTTCTCCATTTTCCCTTGACG
ATGTCACGAATGAAGGGAATTACAAGACTAAGTGGGACGATATTATGCACCGT
GTTTATGACGCGTTTGGGACGCCCAAGGAGGAAAGACTAAATATAGGTCACTG
GTTGAAGAGT
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pGal

dUTPase
(yeast, human,
or T. brucei)

Terminator

pURA3
URA3

Figure 9: General structure of plasmids containing yeast, human, and T. brucei
dUTPase genes.
The dUTPase genes are under the control of a galactose inducible promoter and
also contain a 3X-HA tag. The inducible promoter allows for controlling its
expression and the HA tag allows for monitoring said expression. The plasmids also
contain a URA3 marker for selectivity on SD-URA plates following LiAc
transformation.
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Plasmids containing vector control, yDUT1, hDUT, and tbdUTPase were
purified and then transformed into YNK425 using standard lithium acetate (LiAc)
yeast transformation protocol and selected for on SD-URA plates. Appropriate
colonies were selected to test for the functional complementation of yDUT1, hDUT,
and tbdUTPase using two assays: CFU assay and growth curves (Table 5 and
Figure 10). Survival rates for Table 5 were calculated relative to the cultures grown
without auxin.

Table 5: CFU assay of YNK425 transformed with vector, yDUT1, hDUT, and
tbdUTPase plasmids.
CFU Assay (50 µM Auxin)
Plasmid

Vector

yDUT1

hDUT

tbdUTPase

Survival

96%

85%

71%

69%
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Figure 10: Assay testing functional complementation following yeast
transformation.
Growth curve of YNK425 transformed with vector, yDUT1, or hDUT plasmids grown
in SD-URA 2% galactose/raffinose media with the addition of indicated concentration
of auxin (0, 50, or 500 µM).
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In Table 5, yDUT1, hDUT, and tbdUTPase plasmids transformed into YNK425
in the presence of auxin are expected to have significantly higher survival rates than
the vector. However, the vector plasmid transformation shows the highest survival
rate when the transformants are grown in the presence of 50µM auxin. The data
shown in Table 5 is just one of the several trials that was performed. All had the
same results where the cell survival of vector transformed YNK425 was not different
or was better from the other three plasmids in presence of 50 µM auxin. Due to
inconsistencies that have been observed before with the CFU assay, the
transformants were tested by generating growth curves using the plate reader.
Figure 10 does not have data for tbdUTPase transformants in YNK425 because of
the low number of colonies formed, which was not sufficient enough to create a
growth curve. Therefore, I proceeded to use only vector, yDUT1, and hDUT
transformants. All cultures were initially diluted to 0.1 OD 600nm to start with an equal
number of cells. The SD-URA 2% galactose/raffinose medium was used which
resulted in a low max OD 600nm of approximately 0.5. The growth of transformed cells
was measured in three different auxin concentrations, 0, 50, and 500 µM. In the
presence of 50 or 500 µM auxin, cells transformed with the vector control was
expected to show a significant inhibition in growth rate because of the degradation
on the native Dut1 with no other dUTPase to complement its loss. However, we
observed that the vector control-transformed cells at both concentrations of auxin
grows almost similar to vector control with no auxin as well as the yDUT1- or hDUTtransformed cells. Both the CFU assay and growth curve analysis were performed
several times giving the same result. To combat this, a few changes were attempted
including using a commercially available SC-URA amino acid mix (Sunrise Science
Products; Prod 1306-030), using YEP-GE 2% galactose media instead of using SDURA 2% galactose/raffinose media, and instead of an ethanol-soluble auxin, using a
water-soluble auxin. All these changes resulted in the same outcome with
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complementation not being able to be proven, due to no cell growth inhibition
observed in cells transformed with the vector control (data not shown).
In an alternative approach to the plasmid transformation, we moved on to
integrating the dUTPase protein-expressing cassette into the yeast genome. A
proper locus to integrate the dUTPase genes into the yeast genome would be where
normal yeast functions would not be disrupted by the integration. In Dr. Kim’s lab, all
of the yeast strains being used are MATa haploid strains, therefore genes involved in
mating functions are considered to be neutral or non-functional genes. One such
gene is the HO gene, encoding an endonuclease necessary for mating type
switching from MATa to MAT! and vice versa [39]. In order to incorporate hDUT and
tbdUTPase into the HO gene, the previously used plasmids consisting of hDUT and
tbdUTPase were modified to included sequences from the HO gene upstream and
downstream of pGal and URA3 marker along with NotI restrictions sites to cut out the
desired region of the modified plasmid. The modified fragments were transformed
into the strain YNK425 and were integrated into the yeast genome via homologous
recombination.
The hDUT and tbdUTPase genes incorporated into the yeast genome are HA
tagged. Therefore, I first checked to see if these proteins were properly expressed in
YNK425 by Western blotting with anti-HA antibody (Figure 11). Both hDUT and
tbdUTPase proteins are well expressed when grown in YEP-GE 2% galactose media
in comparison to just YEP-GE media, in which they should not be expressed due to
the absence of galactose.
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YEP-GE + Galactose

YEP-GE

hDUT
@ HO
!-HA
tbdUTPase
@ HO

Figure 11: Western blot showing expression of HA tagged hDUT and tbdUTPase
proteins. hDUT (top) and tbdUTPase (bottom) genes were integrated into the yeast
genome at the HO locus followed by Western blots to confirm expression. The new
strains were grown in YEP-GE 2% galactose media allowing for their expression.
Bands for tbdUTPase are shown white when the image was captured because the
gel was overloaded with the extract collected. Bands present below tbdUTPase is
most likely the degraded tbdUTPase protein.
After confirming expression, next I tested if the dUTPase genes integrated into
the yeast genome in the strain YNK425 would give the expected results: when grown
in YEP-GE with auxin both strains with hDUT and tbdUTPase should show significant
inhibition of growth because the endogenous yDUT1-AID will be degraded and
galactose is not present to induce the expression of hDUT and tbdUTPase.
Inversely, when grown in YEP-GE 2% galactose media with auxin the strains should
exhibit no inhibition in growth, because although auxin’s presence causes the
endogenous yDut1-AID to degrade, the expression of hDut and tbdUTPase is
induced due to the presence of galactose ultimately showing functional
complementation. Functional complementation of these new strains was tested by
creating growth curves (Figure 12). The following statements about Figure 12 apply
to both hDUT (top graph) and tbdUTPase (bottom graph). When ydut1-AID strain
(YNK425) is treated with 500 µM auxin in both YEP-GE and YEP-GE-galactose
(YEP-GE-Gal) the growth is significantly inhibited as expected. When human and T.
brucei dUTPase genes were added and grown in YEP-GE, they do not show any
signs of inhibited growth in the presence of auxin, even though they are expected to
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behave similarly to YNK425 since galactose is not present to induce the expression
of the dUTPase gene. When grown with galactose in the presence of auxin, the
strain grows similarly to when auxin is not present, which suggests that the human
and T. brucei dUTPase genes may be able to functionally complement when the
native yDut1-AID is degraded. However, since the new strains did not have growth
inhibition in the presence of auxin when grown in only YEP-GE, that functional
complementation does not appear to be actually occurring.
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Figure 12: Growth curves testing functional complementation of hDUT and
tbdUTPase genes integrated into the yeast genome in the HO gene.
hDUT (top) and tbdUTPase (bottom) genes were integrated into the yeast genome
and tested for functional complementation in the presence of galactose and 500 µM
auxin via growth curves.
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To check if the result shown in Figure 12 is possibly functional
complementation, a negative control was created that mimicked the integration of a
dUTPase gene into the HO locus. For the negative control, the same plasmid
consisting of tbdUTPase under the control of pGal, a URA3 marker, and flanking HO
sequences was cut using the restriction enzyme SpeI. Within the tbdUTPase
sequence, SpeI is capable of cutting at two locations, which allowed a significant
portion of the gene to be removed and the plasmid was religated, creating a plasmid
containing an inactive tbdUTPase gene. This plasmid was transformed into YNK425
and the addition of the inactive tbdUTPase gene into the HO gene was confirmed
with PCR (data not shown). The growth of this new strain, YNK760 (now referred to
as ‘Neg’ for negative control) was tested by creating growth curves (Figure 13). The
Neg strain was grown alongside YNK425 and is expected to grow similarly to it in
both YEP-GE and YEP-GE with galactose in the presence and absence of 500 µM
auxin. In both mediums, we observed that, when Neg is grown with 500 µM auxin, it
does not show any signs of growth inhibition. Because we failed to demonstrate the
growth inhibition of the Neg strain in the presence of auxin, we do not have the
proper control to demonstrate that the expression of hDUT and tbdUTPase in the
presence of galactose could be complementing the absence of the native yDut1.
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Figure 13: Growth curves showing growth behavior of inactive tbdUTPase
integrated into the HO gene.
YEP-GE (top) and YEP-GE with galactose (bottom) mediums were used to grow
YNK425 and Neg strains with and without 500 µM auxin. Inactive tbdUTPase gene
was integrated into the HO gene of YNK425 to create the Neg strain.
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This outcome led us to question whether or not the endogenous yDUT1-AID
was being degraded in these newly created strains with new dUTPase genes. Similar
to Figure 7, Western blots were carried out to monitor the degradation of the 3X-Flag
tagged ydut1-AID (Figure 14). Two sets of cell extracts were collected at three
timepoints, 0, 1, and 2 hours, one set without auxin and the other with 500 µM auxin.
As shown in Figure 15, over the course of the two hours, the endogenous ydut1-AID
protein in the original YNK425 degrades in the presence of auxin. However, in
strains with the integration of hDUT, tbdUTPase, or Neg cassette at the HO locus,
the endogenous ydut1-AID is not degraded when treated with 500 µM auxin. The
integration of the dUTPase sequences into the yeast genome seems to somehow
interfere with AID system, no longer allowing for ydut1-AID to be degraded. Overall,
the methods and experiments mentioned here were not able to prove
complementation did in fact occur. Therefore, other experiments were conducted as
an alternative method to target T. brucei dUTPase with a small molecule.
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Figure 14: Western blot tracking the degradation of endogenous ydut1-AID. Cell
extracts were collected at 0, 1, and 2 hour timepoints to create a Western blot
showing the degradation of the 3X-Flag tagged endogenous yDut1 when treated
without auxin (top) and when treated with 500 µM auxin (bottom).
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3.3

High throughput virtual screen for T. brucei dUTPase ligands using
Schrödinger’s suite
Significant structural differences exist between human and T. brucei dUTPase

proteins suggesting that it would be feasible to find a small molecule inhibiting the
function of T. brucei dUTPase with little effect on human dUTPase. Since we were
not able to set up complementation system using S. cerevisiae as a model system,
which would have been a necessary tool in screening for such small molecule in
vivo, an alternative method to perform a drug screen is a virtual or computational
approach. This component of the project was made possible thanks to the
collaboration with Dr. John Tainer at MD Anderson Cancer Center who provided us
access to the software and the virtual drug screen was performed by Dr. Nayun Kim.
With crystal structures available online from other studies of human and T. brucei
dUTPases, a virtual drug screen was performed utilizing Schrödinger’s Suite. Being
able to conduct a virtual drug screen rather than a physical one in multiple-well
plates is a much faster and efficient process, allowing for thousands of small
molecules available online to be tested with the protein of desire [33]. In our case,
we know the best fitting molecule that binds to the binding pocket of the dUTPases is
dUTP/dUMP (Figure 15). Therefore, small molecules that are similar in structure to
dUTP/dUMP would be the best candidates for the purpose of this project.

51

Figure 15: T. brucei dUTPase residues interacting with dUMP.
This interaction map was generated using PyMol software. dUTPase cleaves off a
pyrophosphate from dUTP, leaving behind dUMP, which can be used in the
thymidine biosynthesis pathway.
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To begin the virtual screen, ligands to be screened needed to be narrowed
down from the thousands available through the online database. Our goal was to
identify a small molecule that binds to T. brucei dUTPase to inhibit its function but
does not bind to human dUTPase. For the HTVS, a custom library of 5000

compounds (called “Tainer 5000”) was selected from the Life Chemical library based
on their variety, low toxicity, small molecular weights, and drug-like properties. This
library was generated by the lab of John Tainer at MD Anderson to use in screening for
ligands that bind to DNA or nucleotide-interacting proteins. Once molecules that bind
to T. brucei dUTPase have been found, they can then be tested to see which ones
do not fit the human dUTPase, which is what we desire. The 1.47 Å resolution T. brucei
dUTPase structure (PDB ID: 4DK2) [25] was uploaded to the Glide program. In order to
screen for ligands that bind to the catalytic pocket of dUTPase, the “Search Space” was
defined as the annotated catalytic center where dUTP/dUMP binds. The dUTPase requires
a magnesium cation (Mg 2+) to be enzymatically active [40]. Several charged residues
(Q21, N25, E48, E51, R215, K227) involved in hydrogen bonding with PO4 and Mg2+ are
located in the catalytic core in addition to several aromatic residues (W41, T76, H82, F83,
Y220). For the virtual screen, the software allowed us to also include magnesium with
the dUTPase crystal structure to have a more accurate representation of the protein.
One caveat of performing a drug screen in this manner is the crystal structure of our
target protein is in a static state, whereas proteins are always in a dynamic state,
which may lead to more molecules being predicted to be positive hits in the screen
[41].
From the virtual docking simulation of the Tainer 5000 library to the catalytic
pocket of TbdUTPase, over 1000+ molecules were predicted as positive hits
(docking score <-6.5; MMGBSA dG bind <-20) (Figure 16). These molecules were
plotted as docking score vs. MMGBSA dG Bind. The docking score indicates how
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well the molecule binds or fits into the binding pocket of the protein structure in
question. The MMGBSA dG Bind can also be referred to as “free energies of
binding”, which indicates how strong of a bond there is between the molecule and
protein structure in question. In addition, the measurements are in log scale,
therefore, the more negative the values are for a molecule, the better it fit into the
binding pocket with a greater binding strength. The virtual docking of Tainer 5000
library was repeated using the annotated structures of human DUT (PDB ID: IQ5U and 3ARA)
[35, 36]. From the positive hits from docking to the tbdUTPase structure, we eliminated any
positive hits to the hDUT in order to find a ligand specific to tbdUTPase but not to hDUT. The
list was narrowed down to 13 molecules by 1) prioritizing lower MMGBSA dG Bind
and docking score, 2) selecting only one among ligands with very similar structures,
and 3) prioritizing molecules with structural similarity to nucleotides (Table 6).
These 13 molecules were provided to us by Dr. John Tainer. Among the 13
molecules, only one had been previously characterized as a drug, #7,
carbamazepine. This is a common anticonvulsant drug that is widely used to control
seizures [42]. Anticonvulsants are commonly used for brain disorders [43], thus must
penetrate into the blood-brain barrier in order to be effective. Since T. brucei
infection at its second stage does get into blood-brain barrier as well, carbamazepine
is a well-suited molecule to potentially target and inhibit the function of T. brucei
dUTPase regardless of the stage of the disease. Carbamazepine also is a wellstudied drug and therefore would not require more studies such as toxicity analysis.
With 13 candidate molecules finalized, these molecules can now be further used to
study their effect on yeast, human and T. brucei dUTPase.
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Figure 16: HTVS result showing positive binding hits for T. brucei dUTPase.
This figure shows the results of the HTVS. T. brucei dUTPase was tested with the
presence of magnesium. The y-axis, docking score, indicates how well ligands fit into
the binding pocket of the structure and the x-axis, MMGBSA dG Bind, indicates how
strong the binding is.
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Table 6: 13 molecules narrowed down by HTVS.
Molecule #

ID Number

Name

1

F2147-0060

5-(aminomethyl)-3-(4-methylphenyl)-1,3oxazolidin-2-one

2

F2162-0006

[5-(4-fluorophenyl)-1,2-oxazol-3yl]methanamine

3

F1905-0500

3-amino-1,2,3,4-tetrahydronaphthalen-2-ol

4

F2189-0253

2-[2-(3-fluorophenyl)-[1,3]thiazolo[3,2b][1,2,4]triazol-6-yl]ethanamine

5

F6541-4753

1-pyrazolo[1,5-a]pyrazin-4-ylpyrrolidin-3-ol

6

F6546-0690

3-(2-benzyl-1,3,3a,4,6,6ahexahydropyrrolo[3,4-c]pyrrol-5-yl)-1,2,5thiadiazole

7

F0348-2551

Carbamazepine

8

F3385-1587

4-[4-(2-bromophenoxy)-1H-pyrazol-5yl]benzene-1,3-diol

9

F1516-4482

pyrido[1,2-a]pyrimidine-2,4-dione

10

F9994-0418

1-(aminomethyl)-4-methyl-2,3dihydroinden-1-ol
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Structure

Table 6. Cont.

Molecule #

ID Number

Name

11

F0916-0420

2-(6-chloro-4-methyl-3,4-dihydro-1Hisoquinolin-2-yl)ethanol;hydrochloride

12

F1364-0012

2-(1-benzhydrylbenzimidazol-2-yl)-1,3benzoxazole

13

F6541-4740

1-(4-methylcyclohexyl)pyrrolidin-3-ol
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3.4

T. brucei/yeast viability testing with molecules found from the high
throughput virtual screen
With the 13 molecules found that virtually bind to T. brucei dUTPase, but not

to human dUTPase, I next proceeded to see if any one of the molecules had a direct
growth-inhibitory effect on T. brucei cells. Since these molecules likely bind to
dUTPase, an essential enzyme, if one of them binds and inhibits the function of
dUTPase in T. brucei, then those cells will no longer be viable and there should be a
significant increase in cell death. I was taught by Dr, Kyu Lee, a postdoc in Dr. Ziyin
Li’s lab, to grow cultures of T. brucei, so that I could perform these tests.
A stock culture of a blood-stream form T. brucei was started and was
replenished with fresh medium when the stock culture was nearing its saturation
point (approximately every 2 days). All of the 13 molecules were dissolved in DMSO,
therefore I first tested different percentages of DMSO, which would be used as a
negative control, to see if they were toxic to T. brucei cultures. The optimal, noncytotoxic DMSO percentage to use for the cultures was determined to be 0.5% (data
not shown). Final concentrations of 10 µM for the 13 molecules and MTX, which was
used as a positive control since it inhibits the essential thymidylate synthesis
pathway, were added to the T. brucei cultures. When diluting the molecules into the
cultures, the concentrations of DMSO in the 48-well plate being used was
approximately 0.3%, therefore, more DMSO was added to reach the final
concentration of 0.5% to match the negative control. All cultures started with an
initial concentration of 5x10 4 cells/mL and cells were counted daily for 4 days with a
hemocytometer. Due to the great amount of time it would take to count all the cells
for a total of 15 samples and risk of leaving T. brucei cultures out of the incubator
too long, the molecules were split up into 4 different sessions (Figure 17). MTX
treatment led to significant signs of cell death whereas the control, (ctrl in Figure
17), showed normal growth. Of the 13 molecules, molecule #4 led to significant cell
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death to the level similar to MTX-induced cell death. Molecule #5 showed a negative
cell growth rate from day 3 to day 4, which may indicate a delayed effect of cell
killing. Unfortunately, no other molecule showed any signs of growth inhibition.
Molecule #4 may be able to kill T. brucei by binding to dUTPase and inhibiting its
function, based on the virtual screen result.
Next, I determined if molecule #4 is a generally toxic molecule and would be
harmful to yeast cells. The same 13 molecules listed in Table 6 were tested on the
yeast strain YNK421 with wild type DUT1 using the plate growth assay. I first
determined what percentage of DMSO is safe to use for YNK421. 0.5% DMSO was
determined to not affect cell growth of YNK421 (data not shown). The 13 molecules
were again tested at the concentration of 10 µM but MTX this time was increased to
500 µM because 10 µM of MTX did not sufficiently inhibit yeast cell growth. Due to
space on the 96-well plate, the 13 molecules were split into two different plate reader
runs (Figure 18). Molecule #4, which inhibited the growth of T. brucei, presumably
by inhibiting the function of dUTPase, had no effect on the growth of yeast. From
this, it can be concluded molecule #4 does not inhibit yeast dUTPase and therefore,
it most likely would also have no effect of human dUTPase, which is highly
homologous to the yeast protein. And, molecule #5, which partially inhibited the
growth of T. brucei, did not affect yeast cell growth.
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Figure 17: Growth curves testing the effect of molecules 1-13 on T. brucei.
T. brucei blood-stream form cultures were grown in triplicates testing the effect of
molecules 1-13 on growth. All samples contain a final 0.5% DMSO and all molecules
are at a final concentration of 10 µM in the 48-well plate.
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Figure 18: Growth curves testing the effect of molecules 1-13 on YNK421.
Growth curves were generated using a plate reader to test the effect of molecules 113 on YNK421 growth. All samples contain 0.5% DMSO and all molecules were
tested at a final concentration of 10 µM. 0.5% DMSO was the negative control and
MTX was the positive control at 500 µM. N=7.
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3.5

Overexpression and purification of yeast, human, and T. brucei dUTPase
proteins
In order to test whether the candidate ligands found through HTVS would

inhibit T. brucei dUTPase, but have no effect on human and yeast dUTPases, we
overexpressed and purified the dUTPase enzymes to directly test the enzymatic
activity in the presence of candidate molecules. Creation of plasmids containing
hDUT and tbdUTPase and their transformation into BL21 cells, along with a vector as
a control, is described under Protein Purification in the Materials and Methods. First,
overexpression after adding IPTG was confirmed for all of the following proteins
before proceeding to protein purification: yDUT1, hDUT, tbdUTPase #1, tbdUTPase
#2, and vector (data not shown). Figure 19 shows the results of the protein
purification process. For hDUT, tbdUTPase #1, and tbdUTPase #2, the proteins were
overexpressed, and a large amount of purified protein was eluted. All bands for the
purified proteins were the expected size: yDUT1 approximately 15 kDa, hDUT
approximately 17 kDa, and tbdUTPase approximately 28 kDa. The purification of the
vector does not contain any prominent bands. The other prominent bands that are
present with hDUT and both tbdUTPase purifications could possibly be multimers of
the proteins. yDUT1, hDUT, and tbdUTPase #1 were also sent for mass spectrometry
to confirm these bands were the correct protein (data not shown).
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Figure 19: Protein purification results of collected fractions and elution.
Protein staining results for the collected fractions and elution of A) yDUT1, B) hDUT,
C) tbdUTPase #1, D) tbdUTPase #2, and E) vector. 5µL of each sample was applied
to the gel. The following states what each of the lanes represent. L: ladder, F1: cell
lysate, F2: column flow through, F3: wash #1 with 50 mM imidazole, F4: wash #2
with 80 mM imidazole, E1-E10: elution aliquots with 500 mM imidazole, F5: leftover
resin in column.
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After the elution fractions were checked by electrophoresis and Coomassie
Blue staining, elution fractions 7-10 from each purification were collected and
combined for each. The combined fractions were then transferred to storage buffer
and stored in 100 µL aliquots as described in the Materials and Methods section.
Table 7 shows the concentrations of the purified proteins calculated using a protein
quantification kit. Figure 20 shows the Coomassie-stained protein images of stored
fractions. With this successful protein purification, these proteins’ enzymatic activity
could be tested to see if molecule #4 is dUTPase specific.
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Table 7: Protein concentrations of purified proteins.
Protein

yDUT1

hDUT

tbdUTPase #1

tbdUTPase #2

vector

Concentration
(mg/mL)

0.353

0.073

0.116

0.089

0.012

1

2

3

4

5

Figure 20: Final protein staining image of purified proteins.
5µL of each final aliquoted protein was run, showing the degree of purity. The
following states what each lane represents. Lane 1: yDUT1, Lane 2: hDUT, Lane 3:
tbdUTPase #1, Lane 4: tbdUTPase #2, and Lane 5: vector.
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3.6

Enzymatic activity of dUTPase proteins
I observed that T. brucei cells were killed in the presence of molecule #4,

however, it was important to determine if the effect is due to specific inhibition of
dUTPase activity. In order to address this, dUTPase proteins (yeast, human, and T.
brucei) were purified. A protein extract from E. coli cells transformed with empty
vector was subjected to the same purification protocol and serves as the negative
control (referred to as “vector”). dUTPase’s function is to convert dUTP to dUMP
and, in that process, a pyrophosphate, PPi, is generated as a by-product. The
generation of PPi can be measured to determine the enzyme’s activity. The PiPer
Pyrophosphate Assay Kit measures the generation of PPi by first converting it to an
inorganic phosphate, Pi. Pi can be detected in a series of reactions ultimately
leading to the generation of resorufin, a redox probe, which emits a fluorescent
signal that can be measured with a plate reader. Following the kit’s protocol, several
runs were performed testing the enzymatic activity of the five purified proteins (Table
8). The kit calls for generating a standard curve by making dilutions of the provided
pyrophosphate standard and then back calculating the amount of pyrophosphate
generated by the enzyme in question. Unfortunately, every time this assay was
performed, the standard provided with the kit did not result in the appropriate
fluorescent values to generate a proper linear curve and the amount of
pyrophosphate generated could not be calculated. Furthermore, every time this
assay was run, it seemed that yDut1 and hDUT were active enzymes but tbdUTPase
#1 and #2 were not active. The tbdUTPase fluorescence values are not significantly
different from the negative control. Thus, it appears that tbdUTPase is not
enzymatically active. In addition, the vector’s fluorescence, which is expected to be
similar to the negative control, was significantly lower. Due to the assay not working
as expected, the purified proteins could not be tested to determine if molecule #4
affects their activity.
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Table 8: PiPer Pyrophosphate assay experiment.
Sample

Fluorescence

Standard Deviation

PPi 100 µM

193.5

18.84

PPi 50 µM

201

6.78

PPi 25 µM

179

20.05

PPi 12.5 µM

169.5

9.47

PPi 6.25 µM

141.75

16.07

PPi 3.125 µM

123.5

12.07

Negative Control

92.25

0.96

Positive Control

657.5

47.68

yDut1

159.25

5.12

hDUT

148.75

6.24

tbdUTPase #1

88.5

3.42

tbdUTPase #2

95.25

7.63

vector

51.75

1.71
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The inconsistent results with the PiPer Pyrophosphate Assay Kit led me to use
an alternate method to measure the enzymatic of dUTPase. It is well known dUTP
(U) can be incorporated into DNA and dUTPase is responsible for inhibiting this by
converting dUTP to dUMP. Based on this property, we used a PCR-based assay to
test the activity of dUTPase and the effect of candidate molecules #4 and #5. When
nucleotides dATP, dTTP, dCTP, and dGTP (A, T, C, and G) are used to form a PCR
product, the PCR product can be visualized via gel electrophoresis. The same can
be done by using nucleotides A, U, C, and G since U can be added to DNA in lieu of
T. When a nucleotide is missing, then no PCR product will form because the
amplification cannot occur completed without the missing nucleotide. When A, C, G,
along with either T or U, are used for PCR and U has been incubated with a
dUTPase before the reaction, U as dUTP will have been degraded to dUMP, which
cannot be incorporated into DNA resulting in no PCR product formed. When T is
incubated with dUTPase, it should have no effect on PCR efficiency since dUTPase
is specific for U. PCR was performed using T7 (TAATACGACTCACTATAGGG) and
M13Rev (CAGGAAACAGCTATGAC) primers and using pGPD2, an arbitrary plasmid,
as a template. In addition, each PCR reaction contained 5 µL of purified dUTPase
protein and 0.3% DMSO. The PCR reactions were repeated with either Taq DNA
polymerase or MyTaq DNA polymerase (modified and licensed product of Bioline).
Figure 21 shows the results of the PCR-based enzymatic activity assay. Both
molecules #4 and #5 were tested. For either DNA polymerases used, the controls
resulted in the proper PCR products forming as expected. Lanes 1 and 2 in both
Figures 21A and 21B show a very prominent band forming when individual
nucleotides are used and U incorporated into DNA can still form a PCR product.
Lane 3 shows when missing a nucleotide, missing T/U, results in no formation of a
PCR product due to incomplete PCR. Lanes 4-8 consist of T nucleotide incubated
with water or one of the four purified proteins. For each lane a prominent band is
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present as expected because dUTPase does not affect dTTP (T). In Figure 21B,
bands in lane 5 are less visible when using MyTaq DNA Polymerase which may be
due to pipetting error. Lane 9 is another control where U incubated with water should
have no effect on PCR product formation. For Lanes 10 and 11 with DMSO only,
yDut1 or hDUT should degrade dUTP leading to no PCR product formation. Similar
results with no PCR product were expected when molecule #4 or #5 are added since
these molecules are not expected to inhibit yeast or human enzymes. For lane 12
where dUTP was treated with TbdUTPase prior to PCR reaction, PCR product was
either significantly reduced (with Taq polymerase) or absent (with MyTaq
polymerase) indicating that tbdUTPase actively degraded dUTP. For the reaction in
lane 12 in the presence of molecules #4 and #5, more prominent PCR products are
expected if either of these molecules inhibit tbdUTPase, so that dUTP is not
degraded to dUMP. However, as shown in in lane 12 of Figure 21A, PCR band is
significantly less present for molecule #4 and not visible at all for molecule #5. For
Figure 21B, bands are not present for both molecules #4 and #5 in lane 12. This
indicates that molecules #4 and #5 may not be dUTPase specific and the killing of T.
brucei cells exhibited in Figure 17 may be due to another pathway being affected.
Lane 13 consisting of the vector control shows prominent bands present as expected
due the absence of dUTPase proteins. Overall, the enzymatic assays performed
failed to show that molecule #4 or #5 is an inhibitor of dUTPase.
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Figure 21: PCR-based dUTPase enzymatic activity assay.
Plasmid pGPD2 was used a template to amplify the approximately 1 kb region
between T7 and M13Rev primers. PCR products were run on 1% agarose gel and
stained with SYBR-Green. A) PCR reactions using Taq DNA Polymerase and B) PCR
reactions using MyTaq DNA Polymerase. For both A and B, the table below states
what each lane contains. Lanes 4-13 all contain A, C, and G as well in addition to T
or U as indicated. Reactions either contained DMSO, molecule #4, or molecule #5 as
indicated on the right of the gel picture. The PCR reactions shown are only a single
replicate from a set of three individual reactions. The average band intensity below
lanes 12 and 13 is calculated in reference to Lane 9; *the quantification for Molecule
#4 under B is an average of 2 replicates.
1: A T C G 4: T incubated with H2O
9: U incubated with H2O
2: A U C G

5: T incubated with yDut1

10: U incubated with yDut1

3: A C G

6: T incubated with hDUT

11: U incubated with hDUT

7: T incubated with tbdUTPase #2

12: U incubated with tbdUTPase #2

8: T incubated with vector

13: U incubated with vector
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Chapter 4: Discussion
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Using S. cerevisiae as a model system is an effective and efficient method to
perform a pharmacological study [44]. Yeast is an easy to manage organism and
experiments can be performed relatively quickly and provide the ability to replicate
results more productively in comparison to other organisms. For the purpose of this
project, yeast was to be used as a model system to express and study the essential
enzyme dUTPase of the parasite T. brucei and also of humans. This is ideal because
yeast is widely used as a model organism to test functions of human genes and
enzymes [45]. In this case, a drug screen would have been performed to find a
molecule that inhibits the function of the dUTPase from T. brucei, but would have no
effect on human dUTPase, along with no effect on yeast itself. Having no harmful
effect on yeast may indicate the found molecule(s) may not be toxic to human cells
as well due to their similarities. Unfortunately, I was not able to use yeast as a model
system to demonstrate functional. That is, the tests performed were not able to prove
that, when human or T. brucei dUTPases were added to the yeast genome, they
functionally complement the absence of endogenous Dut1 in the strain YNK425 in
the presence of auxin.
Due to the fact that a physical drug screen could not be performed with yeast
cells containing human and T. brucei dUTPase, we chose to perform a virtual drug
screen. The Glide platform allowed for thousands of molecules available through
their online database to be screened against tbdUTPase. The HTVS screen is the
fastest screening tool in the software, which does leave room for error in terms of
finding the right molecule and may have led to extra positive hits. However, because
we also needed to determine if those molecules bound to hDUT, we allowed for a
more stringent screen to be performed. The 13 molecules were found that fit our
criteria of 1) binding to tbdUTPase, 2) not binding to human dUTPase, 3) drug-like
chemical property, and 4) nucleotide-like structure. The list included a well-known
drug carbamazepine. These molecules were tested directly on T. brucei. If none of
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these molecules showed any signs of killing the parasite, then a different approach
would have been taken to find something that targets the essential dUTPase
enzyme.
Out of the 13 molecules tested, molecule #4 was shown to significantly kill T.
brucei with another molecule (#5) showing partial killing. 13 molecules is not a lot of
candidates to screen through so for one to give the desired result was again very
promising. Next, we tested whether molecule #4 was a dUTPase specific inhibitor, or
whether its presence affected another pathway or essential enzyme leading to the
parasite’s cell death. Being able to purify our proteins of interest, allowed us to
directly test if molecule #4 is indeed inhibit dUTPase activity. Both the PiPer
Pyrophosphate Assay Kit and PCR-based dUTPase enzymatic activity assay, which
are standard methods to test the activity of dUTPases in the presence of molecule
#4. Although the results of the PiPer assay were inconclusive due to the failure of
controls, the results of PCR-based assay showed all of the positive and negative
controls were working properly. However, this assay showed that neither molecule
#4 or #5 is an inhibitor of dUTPase.
There are a few different things that could be done to possibly achieve better
results. Firstly, modifying the experiments that have already been done could provide
us with our expected results. The AID system was used as a conditional knockdown
method to be able to study the essential protein dUTPase. As stated, and shown in
the results, the AID system was not very consistent when it came to growing cultures
in the presence of auxin. Several times the survival rates and growth curves were
not as expected due to the possible growth of suppressor mutations, which rendered
the AID system ineffective. In our lab, the pTET system has been successfully used
to create conditional knockouts. The endogenous yDUT1 could be under the control
of a tetracycline inducible promoter (pTET). Human and T. brucei dUTPase genes
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could be transformed into the cells and the expression of the endogenous yDUT1
could be turned off, allowing for complementation to occur.
Another experiment that may be changed would be protein purification.
Protein purification can be a rigorous process and does indeed take a significant
amount of time to get the proper overexpression and washing conditions to get a
valuable, pure purified protein. Revisiting the purification protocols and trying
different overexpression inducers, protein tag, and washing buffers could most
definitely result in a purer sample to be purified.
When the dUTPase genes were integrated into the yeast genome at the HO
locus, the AID system no longer seemed to be properly functioning. Instead of
adding the dUTPase genes at a different locus, the genes can be directly added to
replace the endogenous DUT1 gene. One of ways to accomplish this is to instead
use a diploid yeast strain. in a diploid strain, there are two copies of DUT1. Either
human or T. brucei dUTPase genes can be swapped out with one of the copies of
the endogenous DUT1 via homologous recombination and the yeast cell will still be
viable because it still contains the other DUT1 copy. Plasmids with the expression
cassette for either hDUT or tbdUTPase can be transformed into the diploid cells. The
diploid cells containing one copy of yDUT1 gene and a plasmid-born hDUT or
tbdUTPase gene can be induced to undergo sporulation, which results in a tetrad of
four haploid spores [46]. These spores can then be separated via micromanipulation,
and then grown in rich medium. If hDUT or tbdUTPase can functionally complement
the loss of yDut1, some of the spores will contain the deletion at endogenous DUT1
locus along with the plasmid. If functional complementation is not possible, no
spores with the deletion at endogenous DUT1 locus will be able to survive.
Another method to test for functional complementation is called plasmid
shuffling. The purpose of plasmid shuffling is to introduce two plasmids to your Uraand Leu- cell strain, one plasmid containing WT yDUT1 with a URA3 marker and the
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second plasmid containing hDUT with a LEU2 marker [47]. First, the strain is grown
in rich media and transformed with the WT yDUT1 URA3 plasmid and cells are
selected for and grown in Ura-. The endogenous DUT1 gene can at this point
deleted without loss of cell viability due to the plasmid expressed DUT1. The second
hDUT-LEU2 plasmid is then also transformed and then selected for in Ura- and Leu-.
Colonies that grow should contain both plasmids. The colonies can be replica plated
onto 5-FOA plates to select for cells that lost the WT yDUT1-URA3 plasmid. If hDUT
can functionally complement the loss of yeast Dut1, colonies containing only the
hDUT-LEU2 plasmid should be viable. The viable cells can then be further tested for
complementation. The same experiments can be done with tbdUTPase-LEU2
plasmid to test whether T. brucei dUTPase enzyme can functionally complement the
yeast protein.
Lastly, we have directly showed that molecule #4 kills T. brucei. The best way
to see how it is killing the cells is by directly studying it in T. brucei. Molecule #4
consists of a single S atom in its structure. A chemically synthetic form of this
molecule could be generated using the radioactive isotope

35

S and then used to treat

the parasite [48]. This synthetic molecule should can be tracked where in the
parasite it localizes to in order to see how the molecule might be affecting the
viability of T. brucei. The

35

S can be tracked with various microscopy and

autoradiography methods.
I was unable to show that the addition of human or T. brucei dUTPase can
complement in the absence of the endogenous yeast dUTPase and failed to identify
a tbdUTPase-specific ligand. However, through this project a single small molecule
was found to kill T. brucei directly and have no effect on yeast. Since the dUTPase
pathway is well studied, I believe it still holds promise in terms of having potential as
viable drug target to combat T. brucei infections. Furthermore, with the world
adapting to computers and technology being involved more and more in all fields,
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virtual drug screening has the potential to change the pharmaceutical industry. The
results presented here show a promising method and provides an opportunity to
pursue other scientific methods to potentially combat T. brucei.
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